What is your feeling toward Biowatch's comment below, and do you think that because exsisting techniques have become more efficient this will dillute the value of the GTCB platform?
"Cell culture techniques used to produce recombinant proteins have become more efficient and cost effective, and the ability to monitor and post-facto modify glycosylation have made great strides since then"
Market Data 
Markets 
AI
